Chembio Diagnostics is a leading developer, manufacturer, licensor and marketer of point-of-care rapid diagnostic tests. The company’s two FDA PMA-approved, CLIA-waived rapid HIV tests are marketed in the United States by Alere, Inc., and the company markets its HIV STAT-PAK line of rapid HIV tests internationally. The Dual Path Platform technology, Chembio’s patented point-of-care test platform technology, is providing the company with a substantial pipeline of business opportunities. For more information, visit the company’s Web site: http://www.chembio.com